Compare Novartis AG (NVS) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Workiva Inc — how do they compare? Novartis AG trades at $142.74 (market cap $268.57B), while Workiva Inc trades at $75.4 (market cap $4.01B). The key difference: Novartis AG is far larger — about 67× Workiva Inc's market cap, and Novartis AG pays a 3.31% dividend while Workiva Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Workiva Inc for 21 Days on average.
| NVS | WK | |
|---|---|---|
Market Cap | $268.57B | $4.01B |
Volume | 1,532,573 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $168.62 | $93.31 |
52-Week Low | $121.80 | $44.31 |
Typical Hold Time | 82 Days | 21 Days |
Enterprise Value | $309.89B | $3.99B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Workiva (WK) trades at $71.53, up 1.95% with a bullish technical signal supported by moving averages. The company shows strong revenue growth with 2026 revenue reaching $966 million and net income turning positive at $47 million. Recent earnings beats and AI product innovations at Amplify 2026 conference highlight operational momentum. Analyst consensus remains strongly bullish with 16 buy ratings and an $86 price target representing 20% upside potential from current levels.
The outlook remains positive with continued earnings growth and AI-driven product expansion driving potential upside. Key risks include high valuation multiples (P/E 85.15) and competitive pressures in the regulatory technology space. The stock's technical positioning near support at $71 suggests near-term stability, while fundamental improvements support longer-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
